Segment 1 establishes the current treatment landscape for HER2-positive metastatic breast cancer (mBC) and highlights key unmet clinical needs.
Back
Frontline and Sequential Strategies in HER2-Positive Breast Cancer: Integrating Emerging Evidence into Practice
This program explored the evolving landscape of HER2-targeted therapies, highlighting recent clinical trial data, real-world implementation, and patient-centered care. Experts discussed guideline-driven treatment decision-making, emphasizing NCCN recommendations as a foundation while accounting for individual patient characteristics, comorbidities, and treatment setting. Strategies for managing therapy-related toxicities, such as interstitial lung disease, cardiotoxicity, ocular, and gastrointestinal effects, were highlighted, with an emphasis on proactive monitoring, patient education, and multidisciplinary collaboration with cardiologists, pulmonologists, neurologists, nurses, and pharmacists. Survivorship planning was emphasized for long-term quality of life, including restoring patient autonomy and addressing persistent side effects. Equitable access to novel therapies was explored, addressing financial toxicity, biomarker testing, infusion logistics, and community-based adoption. Finally, the program discussed the importance of ongoing clinician education, digital resources, and patient engagement, reflecting a rapidly evolving field that balances cutting-edge science with practical, patient-centered implementation across diverse practice settings.
Frontline and Sequential Strategies in HER2-Positive Breast Cancer: Integrating Emerging Evidence into Practice
Episodes
All
All
Experts discuss evolving strategies and unmet needs in HER2-positive breast cancer treatment, focusing on emerging therapies and clinical trial insights.
Experts discuss the evolving strategies in HER2-positive breast cancer treatment, focusing on maintenance therapies and patient-specific approaches.
New trials reveal T-DXd's effectiveness in high-risk HER2-positive breast cancer, showing significant improvements in treatment response rates.
Experts unpack second-line HER2+ breast cancer choices, why T-DXd leads, and when T-DM1 or tucatinib matters—especially with brain mets.
Experts weigh how early HER2 escalation with T‑DXd reshapes metastatic sequencing, with tucatinib options and APHINITY’s long-term signals.
Experts weigh HER2+ metastatic options after T‑DXd, balancing tucatinib CNS benefit, ADC‑after‑ADC evidence, and patient toxicity or comorbidities.
Infusion bottlenecks, prior authorizations and travel barriers limit access to new HER2 therapies; upcoming trials test better sequencing and equity.
Clinicians show how to tailor HER2 treatment beyond guidelines, using proactive education and monitoring to curb ADC/TKI toxicities.
This segment emphasizes that multidisciplinary collaboration and survivorship planning are essential to safely deliver HER2-targeted therapies and support long-term patient outcomes.
This segment emphasizes the need to ensure equitable access to novel HER2-targeted therapies through financial and logistical support, accurate biomarker testing, and effective knowledge dissemination to community clinicians.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
5